Standout Papers

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residu... 2013 2026 2017 2021 497
  1. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study (2013)
    David M. Ross, Susan Branford et al. Blood

Immediate Impact

3 from Science/Nature 53 standout
Sub-graph 1 of 20

Citing Papers

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
2025 Standout
Principles and therapeutic applications of adaptive immunity
2024 Standout
16 intermediate papers

Works of Cassandra Slader being referenced

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
2013 Standout
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
2010

Author Peers

Author Last Decade Papers Cites
Cassandra Slader 642 778 81 383 20 1.0k
Rick E. Blakesley 944 1092 121 617 24 1.4k
L Steinmann 709 701 82 182 20 1.2k
W. Demary 225 328 75 740 16 1.2k
Ronald Rosenburg 203 348 74 843 11 1.2k
Donald E. Holdsworth 292 325 219 735 13 1.2k
Lotta Ljung 146 312 27 921 42 1.2k
J. Sydney Stillman 94 598 67 464 23 1.4k
S M van der Kooij 269 354 62 956 17 1.1k
Steven Wees 234 360 54 911 12 1.2k
Apostolos Kontzias 166 363 21 301 31 1.3k

All Works

Loading papers...

Rankless by CCL
2026